Roswell Park received more than $21.8 million in recent competitive grants and contracts to launch new investigations or continue major research efforts. This includes funding from NCI's Cancer Moonshot program as well as renewals for high-impact projects based at Roswell Park.
Bristol-Myers Squibb Co. has completed its acquisition of Celgene Corp. following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, approval by Bristol-Myers Squibb and Celgene stockholders. It completed the acquisition Nov. 20.
Questions on flavored vaping products dominated the Nov. 20 Senate confirmation hearing for Stephen M. Hahn, the administration's pick for the job of FDA commissioner.
FDA granted Exact Sciences' DNA methylation based liquid biopsy test Breakthrough Device designation for detection of hepatocellular carcinoma, based on recently presented data.
FDA has accepted Bristol-Myers Squibb's supplemental Biologics License Application and granted Breakthrough Therapy Designation for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib.
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a supplemental New Drug Application to FDA seeking approval to expand the Imbruvica (ibrutinib) label to include the combination with rituximab for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Health Canada has approved Imbruvica (ibrutinib) in combination with obinutuzumab for treatment-naïve patients with active chronic lymphocytic leukemia.
UroGen Pharma paid $10 million to Agenus Inc. for access to zalifrelimab (AGEN1884, anti-CTLA-4 antibody) for use with sustained release technology for intravesical delivery in patients with urinary tract cancers.
Ashwani Rajput, a cancer surgeon and researcher with an interest in health care disparities, was appointed director of the Kimmel Cancer Center at Johns Hopkins for the Washington, D.C., region.
W. Kimryn Rathmell received the Kidney Cancer Association's Eugene P. Schonfeld Award that recognizes health care professionals who have made significant contributions in the treatment of renal cell carcinoma.
